Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
59 Mrsa Trials Near You
Power is an online platform that helps thousands of Mrsa patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowermRNA-4157 + Pembrolizumab for Cancer
Cleveland, Ohio
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Psychiatric Disorders, Substance Abuse, Others
Must Not Be Taking:Immunosuppressants, Steroids, Chemotherapy, Others
242 Participants Needed
mRNA-2752 + Durvalumab for Advanced Cancers
Cleveland, Ohio
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Active Infection, Autoimmune Disorders, Others
Must Not Be Taking:Immunosuppressants, Anticoagulants, Others
134 Participants Needed
Mesalamine for Ulcerative Colitis
Cleveland, Ohio
This trial is testing mesalamine capsules to see if they are safe and effective for children with Ulcerative Colitis. The medication helps reduce inflammation in the colon. About 80 children will take the capsules regularly for several months, and their health will be monitored through regular check-ups and tests. Mesalamine has been shown to be effective in maintaining remission in ulcerative colitis and is well-tolerated.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:5 - 17
Key Eligibility Criteria
Disqualifiers:Abnormal Exam, ECG, Others
Must Be Taking:Mesalamine
80 Participants Needed
mRNA-1608 Vaccine for Genital Herpes
Beachwood, Ohio
This trial is testing a new vaccine called mRNA-1608 in people who frequently get genital herpes. The vaccine aims to help their immune system recognize and fight the herpes virus, which could reduce how often and how severely they get outbreaks.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Not Listed
365 Participants Needed
mRNA Vaccine for Flu
Lexington, Kentucky
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Influenza, Malignancy, Immunodeficient, Neurological, Others
Must Not Be Taking:Immune-modifying Drugs
843 Participants Needed
The primary aim of this study is to evaluate the reported pain intensity following placement of Orthodontic separators on healthy volunteers aged 18-49 in relation to their recorded physical activity level.
Hypothesis 1: The investigators hypothesize that participants with higher daily step counts and physical activity levels will report significantly less pain intensity from orthodontic separators than their less active peers following separator placement. Null hypothesis is that participants with higher daily step counts will report the same pain intensity from orthodontic separators than their less active peers following separator placement
The secondary aim is to describe the course of pain, at 24 hr intervals, over the next seven days following separator placement.
Hypothesis 2: The investigators hypothesize that more physically active participants will report ratings of zero pain intensity faster (sooner) than their less active peers throughout the one week study. Secondary null hypothesis is that more physically active participants will report ratings of zero pain intensity at the same rate as their less active peers throughout the one week study.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 49
Key Eligibility Criteria
Disqualifiers:Chronic Pain, Missing Teeth, Others
Must Not Be Taking:Analgesics, Opioids, Nerve Pain
94 Participants Needed
Sural Nerve Graft for Parkinson's Disease
Lexington, Kentucky
This phase I double-blind study focuses on the safety and feasibility of implanting autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in persons who have been diagnosed with either Parkinson's disease (PD) or Multiple System Atrophy (MSA). 7 participants will be enrolled, with 4 participants receiving the graft and 3 receiving a sham surgery. Eligible participants will be early in their diagnosis with a lower burden of symptoms. Participants will be followed initially for one year after surgery.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:40 - 75
Key Eligibility Criteria
Disqualifiers:Previous PD Surgery, Major Psychiatric Disorder, Others
Must Not Be Taking:Neuroleptics, Anticoagulants
7 Participants Needed
mRNA-1273.214 Vaccine for Infant COVID-19
Lexington, Kentucky
This trial will test a new COVID-19 vaccine in young infants to ensure it is safe and effective. The vaccine works by using mRNA to teach the body to fight the virus.
Trial Details
Trial Status:Active Not Recruiting
Age:2 - 6
Key Eligibility Criteria
Disqualifiers:Not Listed
700 Participants Needed
mRNA Vaccine for Cytomegalovirus (CMV)
Lexington, Kentucky
The main purpose of the extension phase of this study is to evaluate the longer-term immune persistence of mRNA-1647 vaccine administered to CMV-seronegative and CMV-seropositive adults who completed Study mRNA-1647-P202 (NCT04232280). For participants in the optional booster phase (BP), the main purpose is to evaluate the long-term immunogenicity and safety of the mRNA-1647 vaccine in both participants receiving a booster dose (BD) and those not receiving a BD, and to additionally evaluate the reactogenicity in participants receiving a BD.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:18 - 40
Key Eligibility Criteria
Disqualifiers:Other CMV Vaccines, Medical Conditions, Others
291 Participants Needed
Lu AF82422 for Multiple System Atrophy
Pittsburgh, Pennsylvania
This trial is testing a new drug called Lu AF82422 to see if it can slow down the progression of multiple system atrophy (MSA). MSA is a rare and worsening neurological condition, and current treatments may not be effective. The study will compare the new drug to determine its effectiveness.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40 - 75
Key Eligibility Criteria
Disqualifiers:Serious Neurological Disorder, Others
Must Not Be Taking:Anti-α-synuclein, Mesenchymal Stem
64 Participants Needed
Brain Stimulation for Mild Cognitive Impairment
Ann Arbor, Michigan
This study will evaluate the effects of a form of non-invasive brain stimulation on brain functioning and memory in cognitively intact older adults (healthy controls, HC) and in those with mild cognitive impairment (MCI).
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:60+
Key Eligibility Criteria
Disqualifiers:Neurological Conditions, Mental Illness, Sensory Impairments, Alcohol Or Drug Abuse, Others
80 Participants Needed
STX-001 + Keytruda for Solid Tumors
Pittsburgh, Pennsylvania
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Organ Transplant, HIV, Others
Must Not Be Taking:Anticoagulants, Immunosuppressants
108 Participants Needed
Immunosuppression Adjustment for Kidney Transplant Recipients
Pittsburgh, Pennsylvania
This study will enroll individuals who have:
* Completed primary series of mRNA COVID-19 vaccine, and
* An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine.
This group of patients is at high risk for severe COVID-19 disease due to pharmacologic immunosuppression and a high prevalence of non-transplant risk factors such as obesity and diabetes.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
400 Participants Needed
mRNA-1345 Vaccine for RSV
Detroit, Michigan
This trial tests the safety and immune response of the mRNA-1345 vaccine in high-risk adults and those with organ transplants. The vaccine uses genetic instructions to help the body recognize and fight the virus.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Myocarditis, Pericarditis, Anaphylaxis, Others
Must Be Taking:Immunosuppressive Therapy
1150 Participants Needed
Rapcabtagene Autoleucel for Systemic Sclerosis
Ann Arbor, Michigan
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Pulmonary Hypertension, Renal Pathology, Hypertension, Others
86 Participants Needed
mRNA-3927 for Propionic Acidemia
Ann Arbor, Michigan
The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:1+
Key Eligibility Criteria
Disqualifiers:Liver Transplant, Kidney Transplant, Others
36 Participants Needed
Lu AF82422 for Multiple System Atrophy
Farmington Hills, Michigan
The main goal of this trial is to evaluate the efficacy and safety of Lu AF82422 for the treatment of participants with Multiple System Atrophy (MSA).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:40 - 75
Key Eligibility Criteria
Disqualifiers:Previous Lu AF82422, Other CNS Diseases, Others
360 Participants Needed
Combination Vaccine for Flu and COVID-19
Valparaiso, Indiana
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Pregnancy, Immunodeficiency, Cancer, Others
Must Not Be Taking:Immune-modifying Drugs, Others
107 Participants Needed
mRNA-1345 Vaccine for Respiratory Syncytial Virus
Saginaw, Michigan
This trial is testing a new vaccine called mRNA-1345 that aims to protect against a lung infection virus known as RSV. The study focuses on pregnant women and their newborns. The vaccine works by teaching the body to recognize and fight the virus using a small piece of genetic material. mRNA-1345 is among the most promising RSV vaccines currently being tested.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 40
Key Eligibility Criteria
Disqualifiers:Anaphylaxis, Drug Abuse, Fever, Others
Must Not Be Taking:MRNA Vaccines
360 Participants Needed
OTX-2002 for Liver Cancer
Chicago, Illinois
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma (HCC) and other solid tumor types known for association with the MYC oncogene.
The study consists of Part 1 (OTX-2002 monotherapy) and Part 2 (OTX-2002 combined with standard of care in hepatocellular carcinoma). Part 1 consists of escalation and expansion, and Part 2 consists of safety run-in and expansion. The objective of Part 1 escalation and Part 2 safety run-in will be safety and tolerability, while anti-tumor activity will be evaluated as the primary endpoint in Part 1 and Part 2 expansion.
No Placebo Group
Trial Details
Trial Status:Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
190 Participants Needed
Why Other Patients Applied
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
mRNA Vaccine + Immunotherapy for Melanoma
Chicago, Illinois
This trial is testing if a combination of a personalized cancer vaccine (mRNA-4157) and an immune-boosting medication (pembrolizumab) can better prevent melanoma from returning in patients who have had their tumors surgically removed. Pembrolizumab has been shown to help prevent the return and spread of melanoma in patients who have had their tumors surgically removed.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, HIV, Hepatitis, Others
Must Be Taking:Pembrolizumab
267 Participants Needed
TEV-56286 for Multiple System Atrophy
Chicago, Illinois
The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).
A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286.
Another secondary objective is to evaluate the safety and tolerability of TEV-56286.
The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:30+
Key Eligibility Criteria
Disqualifiers:Substance Abuse, Pregnancy, Vulnerable Populations, Others
200 Participants Needed
AI-Powered Remote Dental Monitoring for Misaligned Teeth
Chicago, Illinois
This trial is testing a new technology called Dental MonitoringTM, which uses 3D images and artificial intelligence to track how teeth move. It aims to help people using clear aligners for orthodontic treatment by customizing when they should change their aligners. The goal is to reduce the need for frequent visits and shorten the overall treatment duration while still achieving good results. Dental Monitoring is a recently introduced orthodontic application that combines safe teledentistry with artificial intelligence (AI) using a knowledge-based algorithm, allowing accurate semi-automatic monitoring of the treatment.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 70
Key Eligibility Criteria
Disqualifiers:Systematic Diseases, Active Periodontal Disease, Others
Must Not Be Taking:Bisphosphonates, NSAIDs
12 Participants Needed
mRNA Vaccines for Lyme Disease
Charlottesville, Virginia
This trial is testing two different vaccines for Lyme disease in healthy adults. One vaccine targets seven parts of the bacteria, and the other targets just one. The vaccines use mRNA to teach the immune system to recognize and fight the bacteria.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Chronic Lyme Disease, Myocarditis, Others
Must Not Be Taking:Immunosuppressants, Immunoglobulins
807 Participants Needed
mRNA Vaccine for COVID-19 and Flu
River Forest, Illinois
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 64
Key Eligibility Criteria
Disqualifiers:Chronic Conditions, Immunodeficiency, Others
Must Not Be Taking:Corticosteroids, Immunosuppressants, Others
932 Participants Needed
COVID-19 Vaccine + RSV Vaccine for Adults 50+
Evansville, Indiana
This study will assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to administration of the vaccines separately in adults aged 50 years and above.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+
Key Eligibility Criteria
Disqualifiers:Not Listed
842 Participants Needed
mRNA VLP Vaccine for COVID-19
Chicago, Illinois
This trial is testing two new vaccines, AZD9838 and AZD6563, in healthy adults to see if they are safe and help the immune system fight COVID-19.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Not Listed
243 Participants Needed
ARCT-032 for Cystic Fibrosis
Northfield, Illinois
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Recent Hemoptysis, Major Surgery, Transplant, Others
Must Not Be Taking:Systemic Corticosteroids
12 Participants Needed
Palatal Expanders for Misaligned Teeth
Naperville, Illinois
The purpose of this study is to compare expansion result and the overall experience between the Invisalign Palatal Expander and the Hyrax expander.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:6 - 11
Key Eligibility Criteria
Disqualifiers:Cleft Palate, Active Caries, Periodontal Disease, TMD, Others
36 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do Mrsa clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do Mrsa clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Mrsa trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Mrsa is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a Mrsa medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest Mrsa clinical trials ?
Most recently, we added Trimethoprim-Sulfamethoxazole for MRSA Infections, mRNA-1083 Vaccine for Influenza and COVID-19 and Sural Nerve Graft for Parkinson's Disease to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.